We feel now is a pretty good time to analyse Spectral Medical Inc.'s ( TSE:EDT )business as it appears the company may be on the cusp of a considerable accomplishment. Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company's loss has recently broadened since it announced a CA$15m loss in the full financial year, compared to the latest trailing-twelve-month loss of CA$42m, moving it further away from breakeven. As path to profitability is the topic on Spectral Medical's investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
Consensus from 2 of the Canadian Biotechs analysts is that Spectral Medical is on the verge of breakeven. They expect the company to post a final loss in 2026, before turning a profit of CA$31k in 2027. Therefore, the company is expected to breakeven just over a year from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 66% is expected, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.
Given this is a high-level overview, we won't go into details of Spectral Medical's upcoming projects, but, keep in mind that generally a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
Check out our latest analysis for Spectral Medical
One thing we would like to bring into light with Spectral Medical is it currently has negative equity on its balance sheet. This can sometimes arise from accounting methods used to deal with accumulated losses from prior years, which are viewed as liabilities carried forward until it cancels out in the future. Oftentimes, losses exist only on paper but other times, it can be a red flag.
Next Steps:
This article is not intended to be a comprehensive analysis on Spectral Medical, so if you are interested in understanding the company at a deeper level, take a look at Spectral Medical's company page on Simply Wall St . We've also compiled a list of essential aspects you should look at:
-
Historical Track Record: What has Spectral Medical's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
-
Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Spectral Medical's board and the CEO's background .
-
Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here .
Have feedback on this article? Concerned about the content? Get in touch
with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature.
We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.
It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
